Radiopharm's RAD101 Shows 92% Success Rate in Detecting Brain Metastases—Pivotal Study Set for 2026
Market Chameleon (Mon, 15-Dec 9:51 AM)
Radiopharm's RAD 101 Hits 92% Concordance in Phase 2b Interim: Strong Early Results Point to Major Market Potential
Market Chameleon (Mon, 15-Dec 7:29 AM)
